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Aims Treatment patterns were compared between randomized groups in EAST-AFNET 4 to assess whether differences
in anticoagulation, therapy of concomitant diseases, or intensity of care can explain the clinical benefit achieved




Cardiovascular treatment patterns and number of visits were compared between randomized groups in EAST-
AFNET 4. Oral anticoagulation was used in >90% of patients during follow-up without differences between ran-
domized groups. There were no differences in treatment of concomitant conditions between groups. The type of
rhythm control varied by country and centre. Over time, antiarrhythmic drugs were given to 1171/1395 (84%)
patients in early therapy, and to 202/1394 (14%) in usual care. Atrial fibrillation (AF) ablation was performed in
340/1395 (24%) patients randomized to early therapy, and in 168/1394 (12%) patients randomized to usual care.
97% of rhythm control therapies were within class I and class III recommendations of AF guidelines. Patients ran-
domized to early therapy transmitted 297 166 telemetric electrocardiograms (ECGs) to a core lab. In total, 97 978
abnormal ECGs were sent to study sites. The resulting difference between study visits was low (0.06 visits/patient/
year), with slightly more visits in early therapy (usual care 0.39 visits/patient/year; early rhythm control 0.45 visits/
patient/year, P < 0.001), mainly due to visits for symptomatic AF recurrences or recurrent AF on telemetric ECGs.
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Conclusion The clinical benefit of early, systematic rhythm control therapy was achieved using variable treatment patterns of
antiarrhythmic drugs and AF ablation, applied within guideline recommendations.
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Introduction
Optimal management of patients with atrial fibrillation (AF) includes
anticoagulation, rate control therapy, and therapy of concomitant
cardiovascular conditions, which may be supplemented by rhythm
control therapy in patients who remain symptomatic on optimal rate
control according to current guidelines.1,2 Even on optimal therapy,
patients with AF remain at high risk of cardiovascular death (1–2%/
year),3–6 worsening of heart failure (3.5% of patients hospitalized for
heart failure/year4,5,7), and stroke despite appropriate anticoagulation
(1%/year8). Indeed, 5% of well-managed AF patients experience these
severe complications per year.6,9
The EAST-AFNET 4 trial demonstrated that systematic, early
initiation of rhythm control therapy results in a 21% relative risk
reduction in a composite of cardiovascular death, stroke, and hos-
pitalization for heart failure or acute coronary syndrome in a pop-
ulation of patients with recently diagnosed AF and concomitant
cardiovascular conditions.9,10 The clinical benefit was achieved with
equal overall safety, including fewer strokes, numerically lower
mortality and more serious adverse events related to rhythm con-
trol therapy in patients randomized to early rhythm control. To
provide context for this finding, and to enable delivery of early
rhythm control therapy in clinical practice, the treatment patterns
used in EAST-AFNET 4 need to be known in detail. Furthermore,
unintended differences in the delivery of other components of AF
therapy such as anticoagulation, therapy of concomitant cardiovas-
cular conditions, or more intensive contacts with the study sites
could have influenced the outcome of the study.
To increase understanding of the trial results and to enable their
clinical implementation,9,11 treatment patterns were compared be-
tween randomized groups in the EAST-AFNET 4 trial population in-
cluding anticoagulation, therapy of concomitant cardiovascular
conditions, rate control therapy, study visits, and rhythm control
therapy.
Methods
This is a comparison of the treatment components between randomized
groups in the EAST-AFNET 4 trial, and of the factors associated with spe-
cific therapies in the EAST-AFNET 4 dataset. The design of the EAST-
AFNET 4 trial, the methods of analysis, and the main results have been
published.6,9 The current analysis was performed on the final, locked
database of the trial. Analyses included treatments at discharge from the
randomization visit, at 1 year of follow-up, and at 2 years of follow-up.
Descriptive data on the use of different therapies, including anticoagula-
tion, therapy of concomitant cardiovascular conditions, rate control, and
rhythm control therapy as well as the number of visits were summarized.
In addition, therapies were classified as guideline-mandated based on the
class I recommendations of ESC practice guidelines in use at the
time.2,12,13 Treatment patterns were described and analysed for differen-
ces between randomized groups, clinical characteristics, and centre and
country effects. Treatment changes over time were analysed and com-
pared between randomized groups.
Continuous variables are reported as mean and standard deviation and
categorical variables are presented as frequencies and percentages. For
visualization, bar plots, box plots, and Aalen–Johansen cumulative inci-
dence curves, accounting for the competing risk of death, were used. To
determine the relation between administered rhythm control (antiar-
rhythmic drug, ablation, or none), anticoagulation therapy and potential
factors (e.g. age, gender, country), we used mixed logistic regression
models adjusted for the random effect of centre. Results are presented as
odds ratios (ORs) together with 95% confidence intervals (CIs).
Mixed logistic regression models were also used to assess differences
between treatment groups in the cardiovascular therapies, participation
of main follow-up visits, and apparent violations of class I recommenda-
tions (or Fisher’s exact test if the mixed logistic regression model was not
applicable). Mixed Poisson and mixed linear regression models were
used to assess differences in the number of visits per patient and the num-
ber of visits per patient per year, respectively. Both model types were
unadjusted and included a random term for the centre effect. All analyses
were performed using STATA 16.1 (StataCorp. 2019) and R 4.0.2 (R
Core Team 2020). The authors had access to the entire, locked database
of the trial and vouch for the fidelity of the data and their analyses.
What’s new?
• Early rhythm control therapy was delivered on top of high
oral anticoagulation rates and high use of rate control in both
randomized groups.
• There were no relevant differences in other cardiovascular
treatments that could explain the outcome of the trial.
• Early rhythm control therapy was achieved with a very low
number of study visits. Telemetric electrocardiogram (ECG)
monitoring with over 300 000 transmitted ECG devices only
resulted in approximately 150 extra visits in 1395 patients
randomized to early rhythm control therapy (ca 0.09 visits/
patient) over five years.
• Confirming other recent trials, the analysis demonstrates the
safety of rhythm control therapy.
• The clinical benefit of early, systematic rhythm control therapy
was achieved using variable treatment patterns of
antiarrhythmic drugs and atrial fibrillation (AF) ablation, applied
within guideline recommendations. These patterns can be
followed to implement early rhythm control therapy for all
patients with recently diagnosed AF and concomitant
conditions.
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Results
Between July 2011 and December 2016, 135 sites in 11 countries
randomized 2789 patients to the EAST-AFNET 4 trial. Over half of
the sites participating in EAST were smaller sites without on-site abla-
tion facilities who cooperated with ablation centres. A total of 1752
patients (63%) were randomized in sites without on-site ablation
facilities (called D-sites, Supplementary material online,TableS1), the
remaining 1037 patients in sites performing AF ablation on-site
(called A-sites). University hospitals randomized 579 (21%) patients,
other hospitals 1276 (46%) patients, and office-based cardiologists
934 (33%) patients.
Over 90% of patients received guideline-mandated oral anticoagu-
lation throughout the follow-up without differences between
................................................................
....................................................................................................................................................................................................................
Table 1 Cardiovascular therapies given to patients in the EAST-AFNET 4 trial at discharge from the baseline visit, at









Patients receiving oral anticoagulation
Anticoagulation (discharge from baseline) 1267/1389 (91.2%) 1250/1393 (89.7%) 2517/2782 (90.5%) 0.149
NOACs (discharge from BL) 800/1389 (57.6%) 763/1393 (54.8%) 1563/2782 (56.2%) 0.103
Vitamin K antagonists (discharge from BL) 467/1389 (33.6%) 490/1393 (35.2%) 957/2782 (34.4%) 0.397
Anticoagulation (12 months FU) 1087/1230 (88.4%) 1121/1241 (90.3%) 2208/2471 (89.4%) 0.111
NOACs (12 months FU) 713/1230 (58.0%) 704/1241 (56.7%) 1417/2471 (57.3%) 0.657
Vitamin K antagonists (12 months FU) 376/1230 (30.6%) 421/1241 (33.9%) 797/2471 (32.3%) 0.100
Anticoagulation (24 months FU) 1020/1159 (88.0%) 1065/1171 (90.9%) 2085/2330 (89.5%) 0.021
NOACs (24 months FU) 690/1159 (59.5%) 699/1171 (59.7%) 1389/2330 (59.6%) 0.774
Vitamin K antagonists (24 months FU) 330/1159 (28.5%) 366/1171 (31.3%) 696/2330 (29.9%) 0.202
Patients receiving rate control therapy (beta adrenoreceptor blocker, verapamil, diltiazem, or digitalis glycosides)
Rate control (discharge from BL) 1088/1389 (78.3%) 1235/1393 (88.7%) 2323/2782 (83.5%) <0.001
Rate control (12 months FU) 883/1230 (71.8%) 1055/1241 (85.0%) 1938/2471 (78.4%) <0.001
Rate control (24 months FU) 799/1159 (68.9%) 986/1171 (84.2%) 1785/2330 (76.6%) <0.001
Patients receiving any rate controlling medication (beta adrenoreceptor blocker, verapamil, diltiazem, digitalis glycosides, or antiarrhythmic drugs with
rate controlling propertiesa)
Patients receiving any rate controlling medication (discharge from BL) 1259/1389 (90.6%) 1250/1393 (89.7%) 2509/2782 (90.2%) 0.382
Patients receiving any rate controlling medication (12 months FU) 1065/1230 (86.6%) 1084/1241 (87.3%) 2149/2471 (87.0%) 0.588
Patients receiving any rate controlling medication (24 months FU) 968/1159 (83.5%) 1013/1171 (86.5%) 1981/2330 (85.0%) 0.042
Patients receiving diuretics
Diuretics (discharge from BL) 559/1389 (40.2%) 561/1393 (40.3%) 1120/2782 (40.3%) 0.987
Diuretics (12 months FU) 508/1230 (41.3%) 521/1241 (42.0%) 1029/2471 (41.6%) 0.788
Diuretics (24 months FU) 478/1159 (41.2%) 507/1171 (43.3%) 985/2330 (42.3%) 0.299
Patients receiving heart failure and antihypertensive therapy (ACE inhibitor, angiotensin receptor blocker, mineralocorticoid antagonists, and neprilysin/
valsartan)
Heart failure and antihypertensive therapies (discharge from BL) 964/1389 (69.4%) 988/1393 (70.9%) 1952/2782 (70.2%) 0.397
Heart failure and antihypertensive therapies (12 months FU) 854/1230 (69.4%) 878/1241 (70.7%) 1732/2471 (70.1%) 0.482
Heart failure and antihypertensive therapies (24 months FU) 798/1159 (68.9%) 837/1171 (71.5%) 1635/2330 (70.2%) 0.163
Patients receiving diabetes therapy (oral antidiabetic medication and insulin)
Antidiabetic therapy (discharge from BL) 256/1389 (18.4%) 254/1393 (18.2%) 510/2782 (18.3%) 0.873
Antidiabetic therapy (12 months FU) 238/1230 (19.3%) 237/1241 (19.1%) 475/2471 (19.2%) 0.870
Antidiabetic therapy (24 months FU) 228/1159 (19.7%) 227/1171 (19.4%) 455/2330 (19.5%) 0.924
Patients receiving statins
Statins (discharge from BL) 628/1389 (45.2%) 568/1393 (40.8%) 1196/2782 (43.0%) 0.016
Statins (12 months FU) 587/1230 (47.7%) 526/1241 (42.4%) 1113/2471 (45.0%) 0.006
Statins (24 months FU) 576/1159 (49.7%) 529/1171 (45.2%) 1105/2330 (47.4%) 0.020
All patient numbers are given split by randomized group and in total. Proportions indicate proportions of patients receiving each therapy at each time point as a fraction of the
totality of patients still in follow-up and with available medication information at that time point. Anticoagulation, therapy with heart failure and antihypertensive drugs, antidia-
betic therapy, and rate control therapy were used in most patients.
ACE inhibitor, angiotensin-converting enzyme inhibitor; BL, baseline visit; FU, follow-up; NOAC, novel oral anticoagulant.
aAntiarrhythmic drugs with rate controlling properties are amiodarone, dronedarone, propafenone, and sotalol. P-values resulting from mixed logistic regression with centre as
random effect.
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randomized groups (Table 1, Supplementary material online, Table S2,
Figure 1). In a multivariate analysis, anticoagulation therapy at any time
was influenced by patient’s age [OR 1.64, 95% CI (1.36–1.98);
P < 0.001], gender [male vs. female OR 1.42, 95% CI (1.42, 95% CI
(1.00–2.01); P = 0.048], and AF pattern [persistent or long-standing
persistent vs. first episode or paroxysmal OR 3.38, 95% CI (1.81–
6.31); P < 0.001], without differences between randomized groups
(P = 0.912). The use of novel oral anticoagulants (NOACs) was high
(>54% at baseline in both groups) with a slight further increase during
follow-up.
Therapy of concomitant cardiovascular conditions appeared well
balanced, with about 70% of patients receiving inhibitors of the renin-
angiotensin-aldosterone system. Blood pressure was not different
between randomized groups throughout follow-up (Table 1,
Supplementary material online, Table S2, Figure 2).
Rate control therapy was used in most patients. Overall, 1088/
1389 (78.3%) patients randomized to early rhythm control therapy
received beta-blockers, verapamil or diltiazem, or digitalis glycosides
at discharge from the baseline visit, and 1235/1393 (88.7%) patients
randomized to usual care. When the use of antiarrhythmic drugs
with rate controlling properties (amiodarone, dronedarone, propafe-
none, or sotalol) was included in the analysis, the difference in rate
control was much less pronounced (Table 1, Figure 3). The use of rate
control decreased during follow-up in both groups, more in patients
randomized to early rhythm control.
In-person visits were infrequent during the median follow-up of
5.1 years per patient due to the study design.6 Patients randomized to
early rhythm control therapy underwent 2974 in-person visits (2.13/
patient, 0.45 visits/patient/year) including 249 visits triggered by de-
tection of recurrent AF calling for an adjustment of rhythm control
therapy (so-called triggered visits),6 slightly more than the 2710 visits
(1.94/patient, 0.39 visits/patient/year) including 93 triggered visits in
patients randomized to usual care (Table 2, Figure 4A). The increase in
site visits seen in patients randomized to early therapy was mainly
driven by triggered visits to adjust rhythm control therapy (Figure 4B).
Patients randomized to early therapy transmitted 297 166 telemetric,
30-s electrocardiogram (ECG) recordings to a core lab. Of these, 97
978 were judged as abnormal and sent to study sites for review and
to decide on clinical consequences. Only a small number of abnormal
telemetric ECGs led to clinical actions: Of the 249 triggered visits
performed in patients randomized to early rhythm control, approxi-
mately 150 were due to abnormal telemetric ECGs.
Of 2789 patients, 508 patients (18.2%) received an ablation at any
time, with 340/1395 (24%) patients randomized to early therapy re-
ceiving ablation. Antiarrhythmic drug therapy was given to 1373
(49.2%) patients, including 1171/1395 (84%) of those randomized to
early therapy. A total of 1208/2789 (43.3%) were managed without
ablation or antiarrhythmic drug therapy throughout the trial [usual
care: 1079/1394 (77%)]. Almost all patients (>97% of those receiving
rhythm control therapy) received rhythm control therapy aligned
Figure 1 Anticoagulation therapy in patients randomized to early rhythm control (left panel) and usual care (right panel) in the EAST-AFNET 4
population at discharge from randomization, 1 year, and 2 years of follow-up. There was no difference in anticoagulation therapy between random-
ized groups. A combination of both was very rare and therefore the yellow bars are hardly visible. aCombination of both can raise due to changes of
medication between visits.
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Figure 2 (A) Use of inhibitors of the renin–angiotensin–aldosterone system in patients randomized to early rhythm control (left panel) and usual
care (right panel) in the EAST-AFNET 4 population.(B) Systolic and diastolic blood pressure during the in-person visits, split by randomized groups.
Blood pressure was not different between randomized groups. aAll Sacubitril and Valsartan are given only in combination with other medications.
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with the class I recommendations in guidelines (Table 3). Some
centres preferentially used AF ablation for rhythm control manage-
ment, reflecting access to therapy and preferences by the local study
teams. Others preferentially used flecainide, propafenone, dronedar-
one, or other amiodarone as initial rhythm control therapy in the ma-
jority of their patients. Adjustments to rhythm control therapy were
relatively common in the first year after randomization, predomi-
nantly in patients randomized to early rhythm control (Figure 5A).
Many ablations were performed immediately following randomiza-
tion to early rhythm control. Thereafter, the number of patients
treated by ablation increased steadily in both randomized groups
(Figure 5B). At 2 years, 270/1395 (19.4%) patients randomized to
early rhythm control therapy had undergone AF ablation, while 97/
1394 (6.9%) patients randomized to usual care had undergone abla-
tion. This corresponded to 26.7% of patients still in follow-up at
2 years. The decision to manage a patient without rhythm control
Figure 3 Use of any rate controlling therapies in patients randomized to early rhythm control (left panel) and usual care (right panel) in the EAST-
AFNET 4 population. This display includes antiarrhythmic drugs with rate controlling properties, namely amiodarone, dronedarone, propafenone,
and sotalol. The use of these medications often obviates the need for additional rate-controlling medication, explaining the lower use of beta block-
ers, calcium channel antagonists, or digoxin shown in A.
....................................................................................................................................................................................................................
Table 2 In-person study visits at 1, 2, and 3 years, triggered and unscheduled visits
Early treatment Usual care P-value
FU 12 months 1230 1241 0.495a
FU 24 months 1159 1171 0.545a
FU 36 months 117 119 0.849a
Triggered visits total (nr. per patient) 249 (0.18) 93 (0.07) <0.001b
Unscheduled visits total (nr. per patient) 219 (0.16) 86 (0.06) <0.001b
Total number of visits total (nr. per patient) 2974 (2.13) 2710 (1.94) <0.001b
FU, follow-up.
aP-value resulting from mixed logistic regression.
bP-value resulting from mixed Poisson regression; both models with centre as random effect.
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therapy was almost exclusively explained by randomized group with-
out any relevant other effects [OR early treatment vs. usual care
0.02, 95% CI (0.02; 0.03); P < 0.001], Figure 6A, Supplementary mate-
rial online, Table S4. The initial choice of the type of rhythm control
therapy varied by centre (Figure 6B). AF ablation was more likely
given to patients randomized to early treatment, patients recruited in
an A-site or in another country than Spain, Italy, or Poland, younger
patients, those without diabetes mellitus, and patients included with
Figure 4 (A) Number of in-person visits split by randomized group. There were 2710 in-person visits in patients randomized to usual care (1.94
visits/patient) and 2974 in-person visits in patients randomized to early rhythm control (2.13 visits/patient) (P < 0.001). (B) Timing of in-person fol-
low-up visits split by randomized group and by visit type. All numbers are displayed as number of visits per day.
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first diagnosed or paroxysmal AF (Figure 6 and Supplementary mate-
rial online, Table S3). If patients randomized to usual care remained
symptomatic despite optimal rate control, the trial protocol called
for rhythm control initiation by means of antiarrhythmic drugs or ab-
lation. The high proportion of patients without AF-related symptoms
(EHRA I) in both randomized groups at two years substantiates the
adequate, protocol-conform use of rhythm control to improve AF-
related symptoms in the usual care arm.
Discussion
Main findings
This in-depth analysis of the therapies given to patients participating
in the EAST-AFNET 4 trial produced three major results.
(1) A strategy of systematic and early rhythm control therapy achieved
clinical benefit when added to evidence-based anticoagulation and
rate control therapy.
(2) There were no relevant differences in other cardiovascular treat-
ments that could explain the outcome of the trial.
(3) EAST-AFNET 4 implemented early rhythm control without many
additional visits: On average, each patient was seen 1.94 (usual care)
and 2.13 (early therapy) times by the study centre during the
follow-up of approximately 5 years.
(4) Early, systematic rhythm control was achieved using a combination
of antiarrhythmic drugs and AF ablation. Early rhythm control treat-
ment patterns varied by site and country within guideline recom-
mendations, outlining a range of ways to provide early rhythm
control therapy to patients with AF.
Anticoagulation
Evidence-based anticoagulation use was high (>90% throughout
follow-up) without differences between randomized groups.
Approximately half of the patients were treated with NOACs at dis-
charge from randomization, increasing slightly at 2 years (Table 1),
comparable to concomitant and more recent large European obser-
vational data sets.14,15 The adequate, continued use of anticoagulants
and the high therapy adherence can explain the low stroke rate
observed in EAST-AFNET 4,9 consistent with reports from large anti-
coagulation trials, and different from the AFFIRM trial.4,16
Concomitant cardiovascular conditions were treated without differen-
ces between randomized groups. Blood pressure, an important sur-
rogate outcome associated with stroke and other cardiovascular
events, was not different between randomized groups. There were
4–6% more patients randomized to early therapy who received sta-
tins. While this difference was significant, and can contribute to a re-
duction in acute coronary syndrome, stroke, and even cardiovascular
death, it is very small. In view of the balanced distribution of therapies
for other cardiovascular comorbidities, the lack of differences in
blood pressure between randomized groups, and in view of the long-
term outcomes of RACE-3,17 where a randomized intervention with
high use of statins, Mineralocorticoid receptor antagonists (MRAs),
and nurse-led care did not improve five-year outcomes (neither for
recurrent AF nor for MACCE, recently presented at EHRA 2021), it
is unlikely that undetected differences in this treatment domain can
explain the differences in outcomes observed in EAST-AFNET 4.
Rate control therapy was given to the vast majority of patients in
EAST-AFNET 4, in line with current guidelines (Table 1). Digoxin was
used in a very small number of patients, and almost entirely as
second-line therapy on top of beta-blockers, following current rec-
ommendations and trial results.18 Whether this remains best practice
in patients with AF and heart failure remains to be tested in light of
the recently published RATE-AF trial.19
Number of visits
The number of study visits was low in both study arms, but
slightly and significantly higher in patients randomized to early
therapy (usual care 0.39 visits/patient/year, early rhythm control
0.45 visits/patient/year, P < 0.001). As can be appreciated in
Figure 4, most of these visits occurred early after randomization,
most likely to adjust rhythm control therapy. The number of ex-
tra visits induced by telemetric ECG monitoring is lower than
expected at the start of the trial.6 As the results of abnormal
telemetric ECG recordings were only revealed to study sites,6
this small increase in study visits will capture almost all additional
.............................................................
....................................................................................................................................................................................................................










Severe coronary artery disease in patients receiving flecainide or
propafenone at discharge
32 (2.3%) 3 (0.2%) 35 (1.3%) <0.001a
Reduced left ventricular function in patients receiving flecainide or
propafenone at discharge
2 (0.1%) 1 (0.1%) 3 (0.1%) 0.572a
Reduced left ventricular function in patients receiving dronedarone
at discharge
3 (0.2%) 0 (0.0%) 3 (0.1%) 0.250b
At least one violation of guideline conform use 37 (2.7%) 4 (0.3%) 41 (1.5%) <0.001a
Over 97% of patients received rhythm control therapy in line with recommendations of the ESC guidelines published between 2012 and 2020.1,10,11 The most common appar-
ent violation was the use of sodium channel blockers in patients with coronary artery disease (35 patients, 1.3%).
aP-value resulting from mixed logistic regression with centre as random effect.
bP-value resulting from Fisher’s exact test.
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visits induced by telemetric ECG monitoring (Table 2, Figure 4A).
Together with the reported finding that there was no difference
in nights spent in hospital between groups,8 these data demon-
strate that early therapy was delivered with few added visits,
and that differences in the intensity of care between groups can-
not explain the observed effects of early therapy on cardiovas-
cular death, stroke, and hospitalizations for heart failure or
acute coronary syndrome. While delivery of care in a controlled
trial will differ from routine clinical care, the excellent delivery
of all domains of AF care in the EAST-AFNET 4 centre net-
works with few planned or unplanned visits may provide exem-
plars for the delivery of holistic, integrated, cost-effective care
for patients with AF.
Rhythm control therapy was well aligned with guidelines, with >97%
of control therapies following accepted class I recommendations
(Table 3).2,12 Early rhythm control was initially delivered as antiar-
rhythmic drug therapy in most patients, and 3=4 of patients were
treated without AF ablation throughout the trial. AF ablation was
used in ca 1=4 of patients randomized to early therapy (Figure 5B), illus-
trating the importance of this treatment modality in the trial. As
expected for early rhythm control, the difference between the use of
AF ablation was most marked in the first few months after randomi-
zation (Figure 5B). In patients randomized to usual care, rhythm con-
trol was used in 15% of patients at 2 years, very similar to general AF
registries reporting rhythm control15,20,21 and at a rate anticipated in
the design of the trial.5 In addition to randomization to early rhythm
Figure 5 (A) Sankey Plot of rhythm control treatment over time per group. Shown is the proportion of patients receiving antiarrhythmic drugs
(AAD) and AF ablation (ablation) at each of the scheduled visits, split by randomized groups, and the proportion of patients changing from one type
of therapy to the other. (B) Time to first AF ablation split by randomized group (Aalen–Johansen cumulative incidence curve). AF ablation was more
often used in patients randomized to early therapy, with a steady increase in both randomized groups over time. At 2 years, 270/1395 (19.4%)
patients randomized to early therapy had undergone AF ablation, while 97/1394 (7.0%) patients randomized to usual care had undergone ablation.
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control, the use of AF ablation was associated with enrolment at
an A-site, younger age, no diabetes mellitus, and with first diag-
nosed or paroxysmal AF (Figure 6A). Furthermore, there were re-
gional differences in the use of AF ablation, probably reflecting
the access to AF ablation at the time of enrolment into the trial
(2011–2016). Furthermore, regional differences in the competence
and practice of antiarrhythmic drug therapy probably drove these
differences.
Figure 6 (A) Multivariate analysis of potential factors influencing the decision to manage patients without rhythm control therapy (None, left panel),
to perform AF ablation (middle panel), and to initiate antiarrhythmic drug therapy (AAD, right panel) at any time. The decision to manage without
rhythm control therapy was almost entirely driven by randomized group. The decision to perform AF ablation was also influenced by younger age,
randomization in an ablation site, diabetes, AF pattern, and country. AF type first, first episode or paroxysmal, persistent, persistent or long-standing
persistent; ET, early treatment; Left ventricular hypertrophy on echocardiography was defined based on the inclusion criterium (>15 mm wall thick-
ness); Severe CAD, severe coronary artery disease (previous myocardial infarction, CABG, or PCI); Stable heart failure was defined as either NYHA
stage II or LVEF < 50%; TIA, transient ischaemic attack; UC, usual care. (B) Choice of initial rhythm control therapy displayed by centre. Displayed is
the proportion of patients receiving each rhythm control therapy option in each centre, limited to centres that initiated rhythm control therapy in at
least five patients. There are clear centre-based preferences in the choice of initial antiarrhythmic drug therapy, with individual sites using AF ablation,
flecainide, propafenone, dronedarone, or other antiarrhythmic drugs in most patients initially. Therapy choices were guideline-conform in almost all
patients.
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Sinus rhythm rates were higher on early rhythm control in EAST-
AFNET 4 (80% at 2 years8) than in AFFIRM22 or AF-CHF,23 illustrat-
ing the effectiveness of the early therapy strategy. The high rate of si-
nus rhythm in the early treatment arm might be explained by the
modern rhythm control therapy patterns including safe use of sodium
channel blockers, treatment with dronedarone, and AF ablation.
These components of rhythm control therapy were not available at
the time of AFFIRM and only rarely use in AF-CHF. The early timing
of rhythm control therapy can furthermore explain the high rate of si-
nus rhythm.24
Treatment patterns used to deliver early
rhythm control therapy
EAST-AFNET 4 was a strategy trial. The vast majority of the rhythm
control therapy options used in EAST-AFNET 4 (ca 97%, Table 3) are
supported by AF treatment guidelines2,12 and led to few safety events
due to antiarrhythmic drug or AF ablation.3,25 EAST-AFNET 4 en-
rolled patients from 2011 to 2016. While the use of AF ablation was
high for the practice at the time, it seems likely that contemporary
rhythm control therapy may make more use of AF ablation in light of
recent data illustrating its safety,3,25 improvement in quality of
life,26,27 and effectiveness in maintaining sinus rhythm.28,29
A high degree of centre-based variation was found in the initial se-
lection of rhythm control therapy. This is in keeping with reports
from the Veterans Administrations database where centre-based
effects were a key determinant of the choice of antiarrhythmic
drug.25 Possible drivers of these differences are local experience, pro-
tocols, access to therapy options, reimbursement, and others.30 The
clinical benefit of early rhythm control was not affected by type of
centre, underpinning that different treatment patterns can be used to
achieve early rhythm control. Important for the interpretation of the
trial is that all centres had access to AF ablation performed in experi-
enced centres.
The current analysis emphasizes the relevance of AF ablation for
safe and effective rhythm control therapy, used in a quarter of
patients randomized to early rhythm control therapy, but also the
effectiveness of antiarrhythmic drugs when initiated early, sufficient in
around 75% of patients to deliver early rhythm control therapy. It is
likely that sinus rhythm, lack of documented or symptomatic AF
recurrences, failure of rhythm control, and patient preferences were
the drivers of discontinuation of rhythm control therapy during the
course of the study in circa 35% of patients randomized to early
rhythm control at 2 years (Figure 5A).
Limitations
While the EAST-AFNET 4 trial enrolled almost 3000 patients in 11
European countries with different healthcare systems, actively enroll-
ing in sites with and without on-site AF ablation, small cardiology
practices and large tertiary care centres, reflecting different treat-
ment patterns and cultures, there may be further, different rhythm
control treatment patterns with equal effectiveness. It is likely that
different patterns and potentially different outcomes could arise
from contemporary delivery of rhythm control, e.g. more AF abla-
tions. It is unclear whether differences in therapy choices had an ef-
fect on outcomes. This requires complex modelling that is beyond
the scope of this analysis.
Conclusions
Different patterns of early rhythm control therapy resulted in lower
rates of cardiovascular death, stroke, and hospitalizations for heart
failure or acute coronary syndrome when added to a comprehensive
management of AF including anticoagulation, therapy of concomitant
cardiovascular conditions, and rate control therapy. There were no
differences between randomized groups other than the study inter-
vention that could explain the difference in clinical outcomes. Early
rhythm control was delivered using different treatment patterns, pro-
viding a range of choices how to deliver early rhythm control therapy
to achieve clinical benefit in patients with AF.
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